세파렉신

세파렉신 · 세파렉신(CEPHALEXIN) · CEFALEXIN · CEFALEXIN SODIUM · oroxin · CEPOREX · CEPHALEXINE · cex

https://huagongshe.com/ko/chemical/27447

식별자 및 물리적 특성

CAS No.	15686-71-2
분자식	C16H17N3O4S
평균 분자량	347.4 g/mol
단동위원소 질량	347.09397721 g/mol
SMILES	CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1
InChIKey	ZAIPMKNFIOOWCQ-UEKVPHQBSA-N
PubChem CID	27447
ChEMBL	CHEMBL1200544
ChEBI	CHEBI:3534
EC No.	239-773-6
DTXSID	DTXSID9022780
현지명	세파렉신

화학 및 물리적 성질

XLogP	0.6
극성 표면적	138
수소 결합 공여자 수	3
수소 결합 수용자 수	6
회전 가능 결합 수	4
무거운 원자 수	24
형식 전하	0
복잡도	600
LogP(분배 계수)	0.65logP = 0.65
Color/Form	CRYSTALSWHITE TO OFF-WHITE, CRYSTALLINE POWDER
용해도	10mg/mLSLIGHTLY SOL IN WATERPRACTICALLY INSOL IN ALC, CHLOROFORM, ETHER2.97e-01 g/LNH4OH 1 M: 50 mg/mL, 투명, 노란색
끓는 점	727.4727.4±60.0 °C(Predicted)
녹는점	326.8326.8 °C196-198°C
Physical Description	Solid
Stability/Shelf Life	ACID-STABLE
Dissociation Constants	2.537.14PKA: 5.2, 7.3
Collision Cross Section	178.5 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]178.02 Å² [M+H]+ [CCS Type: TW182.19 Å² [M+K]+ [CCS Type: TW163.36 Å² [M+H-H2O]+ [CCS Type: TW182.91 Å² [M+Na]+ [CCS Type: TW183.1 Å² [M+Na]+ [CCS Type: TWMethod: calibrated with Waters Major Mix]186.9 Å² [M+H]+ [CCS Type: TW179.56 Å² [M-H]-
밀도	1.3040 (rough estimate)
굴절률	1.6320 (estimate)
저장 조건	Keep in dark place,Inert atmosphere,2-8°C
pKa(산도 계수)	5.2, 7.3(at 25℃)
물리적 상태	Solid
색상	White to light yellow
pH	pH (5g/l, 25℃) 3.5～5.5
용해도	12.5g/L(25℃)
Merck	13,1986
BCS Class	4
주요 응용	법의학 및 독성학의약품(소분자)
InChI	1S/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1
InChIKey	AVGYWQBCYZHHPN-CYJZLJNKSA-N
SMILES	N[C@@H](C(N[C@@H]1C(N2[C@]1([H])SCC(C)=C2C(O)=O)=O)=O)C3=CC=CC=C3
EPA	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-methyl-8-oxo-, (6R,7R)- (15686-71-2)

화학적 성질

White cryst. powder

안전 및 규제

GHS 분류	DangerH317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]H334 (100%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]P233, P260, P261, P271, P272, P280, P284, P302+P352, P304+P340, P321, P333+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 75 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
규제 정보	5-Thia-1-azabicyclo4.2.0oct-2-ene-2-carboxylic acid, 7-(2R)-aminophenylacetylamino-3-methyl-8-oxo-, (6R,7R)-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.Cephalexin: Does not have an individual approval but may be used under an appropriate group standard
기타 안전 정보	IMAP assessments - 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-methyl-8-oxo-, [6R-[6.alpha.,7.beta.(R)]]-: Human health tier I assessmentIMAP assessments - 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-methyl-8-oxo-, [6R-[6.alpha.,7.beta.(R)]]-: Environment tier I assessment
FDA 요건	Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended21 U.S.C. 321-392).
Hazard Classes and Categories	Skin Sens. 1 (100%)Resp. Sens. 1 (100%)
보관 조건	Cephalexin capsules, tablets, and powder for oral suspension should be stored in tight containers at a temperature less than 40 °C, preferably between 15-30 °C. After reconstitution, cephalexin oral suspensions should be stored at 2-8 °C and discarded if not used within 2 wk.

용도

개요

Use of the ampicillin-type side chain conveys oral activity to cephalexin. Whereas it no longer has an activating side chain at C-3 and, as a consequence, is somewhat less potent, it does not undergo metabolic deactivation and, thus, maintains potency. It is rapidly and completely absorbed from the GI tract and has become quite popular. Somewhat puzzling is the fact that the use of the ampicillin side chain in the cephalosporins does not result in a comparable shift in antimicrobial spectrum. Cephalexin, like the other first-generation cephalosporins is active against many Gram-positive aerobic cocci but is limited against Gram-negative bacteria. It is a widely used drug, particularly against Gram-negative bacteria causing urinary tract infections, Gram-positive infections (Staphyl ococcus aureus, Streptococcus pneumoni ae and Streptococcus pyogenes) of soft tissues, pharyngitis, and minor wounds.

용도

Antibacterial.